NeuroSense Therapeutics Ltd. (NRSNW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Herzliya, イスラエル. 現CEOは Alon Ben-Noon.
NRSNW を有する 17 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $4.88M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
